Forecyte Bio Expands with New Cell and Gene Therapy GMP Facility in Shanghai

Maryland-based Contract Development and Manufacturing Organization (CDMO) Forecyte Biotechnologies has announced the opening of a new, state-of-the-art cell and gene therapy (CGT) GMP facility in Shanghai on March 31. This marks the company’s second facility, following the opening of a US-based facility in January.

Investment and Global Impact of the New Facility
The 140,000-square-foot facility represents an investment of nearly USD 40 million, enabling Forecyte to provide clients worldwide with multiple GMP production lines for plasmids, viral vectors, and cell therapies. This expansion underscores Forecyte’s commitment to advancing the cell and gene therapy sector by offering cutting-edge manufacturing capabilities.

Strategic Advantages of Dual US and China Sites
The dual sites in the US and China offer significant advantages to CGT companies, particularly those with intentions to file for international approvals. This global footprint allows for streamlined operations and regulatory filings, catering to the needs of a diverse client base in the rapidly growing CGT industry.-Fineline Info & Tech

Fineline Info & Tech